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Pediatric severe asthma with fungal sensitization
is mediated by steroid-resistant IL-33
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Andrew Bush, MD,a,d Clare M. Lloyd, PhD,b* and Sejal Saglani, MDa,b* London, United KingdomBackground: The mechanism underlying severe asthma with
fungal sensitization (SAFS) is unknown. IL-33 is important in
fungus-induced asthma exacerbations, but its role in fungal
sensitization is unexplored.
Objective: We sought to determine whether fungal sensitization
in children with severe therapy-resistant asthma is mediated by
IL-33.
Methods: Eighty-two children (median age, 11.7 years; 63%
male) with severe therapy-resistant asthma were included. SAFS
(n 5 38) was defined as specific IgE or skin prick test response
positivity to Aspergillus fumigatus, Alternaria alternata, or
Cladosporium herbarum. Clinical features and airway
immunopathology were assessed. Chronic exposure to house dust
mite and A alternata were compared in a neonatal mouse model.
Results: Children with SAFS had earlier symptom onset (0.5 vs
1.5 years, P 5 .006), higher total IgE levels (637 vs 177 IU/mL,
P 5 .002), and nonfungal inhalant allergen-specific IgE.
Significantly more children with SAFS were prescribed
maintenance oral steroids (42% vs 14%, P 5 .02). SAFS was
associated with higher airway IL-33 levels. In neonatal mice A
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312IL-33 levels, and IL-131 innate lymphoid cell (ILC) and TH2
cell numbers but similar airway hyperresponsiveness (AHR)
compared with those after house dust mite exposure. Lung
IL-33 levels, IL-131 ILC numbers, TH2 cell numbers, IL-13
levels, and AHR remained increased with inhaled budesonide
during A alternata exposure, but all features were significantly
reduced in ST22/2 mice lacking a functional receptor for IL-33.
Conclusion: Pediatric SAFS was associated with more oral
steroid therapy and higher IL-33 levels. A alternata exposure
resulted in increased IL-33–mediated ILC2 numbers, TH2 cell
numbers, and steroid-resistant AHR. IL-33 might be a novel
therapeutic target for SAFS. (J Allergy Clin Immunol
2015;136:312-22.)
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Atopy is a prominent characteristic of severe pediatric asthma,1
and many allergens can exacerbate disease, including
fungal exposure both outside and indoors.2,3 In adults fungal
sensitization is associated with increased asthma severity,
morbidity, and mortality, including higher rates of hospital and
intensive care unit admission.2 In children with persistent symp-
toms, asthma with fungal sensitization was associated with worse
disease severity, increased bronchial reactivity, increased airway
eosinophilic inflammation,4 and more exacerbations.5
Although an association between fungal sensitization and
increased morbidity is apparent, whether such an association is
causal remains unconfirmed.6,7 Recently, a subphenotype of
severe asthma with fungal sensitization (SAFS) has been
described in adults8,9 and is associated with reduced lung func-
tion and increased morbidity.10,11 The definition of SAFS in-
cludes severe asthma treatment at British Thoracic Society
level 4 or equivalent; fungal sensitization demonstrated by a
positive skin prick test (SPT) response or specific IgE (sIgE)
to at least one of 7 fungi (ie, Aspergillus fumigatus, Alternaria
alternata, Cladosporium herbarum, Penicillium chrysogenum,
Candida albicans, Trichophyton mentagrophytes, or Botrytis
cinerea); and no evidence of allergic bronchopulmonary asper-
gillosis (ABPA8; a very rare diagnosis in asthmatic children).
Little is known regarding the pathogenesis of pediatric
SAFS. A single case report described dramatic improvement
with oral itraconazole.12 A retrospective review of adults
with ABPA or SAFS in whom therapy with itraconazole had
failed showed a significant improvement in asthma severity
when treated with the second-line antifungal agents voricona-
zole or posaconazole.13 A randomized controlled trial of itra-
conazole in adults with SAFS showed a significant
improvement in quality of life.14 However, a further trial of
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sensitization to A fumigatus did not show any benefit.15 Recently,
IL-33 has been shown to contribute to the development of fungal
exacerbation of allergic airways disease in an adult murine model
after chronic house dust mite (HDM) exposure.16 However,
mechanisms underlying chronic fungal exposure and sensitiza-
tion remain unknown. We hypothesized that fungal sensitization
in children with severe therapy-resistant asthma (STRA) is
associated with more severe disease and is mediated by the innate
cytokine IL-33. We investigated the clinical and pathologic
features of fungal sensitization in children with STRA and
delineated mechanistic differences underlying chronic fungal
and HDM exposure in a neonatal mousemodel of allergic airways
disease.METHODS
Subjects
Children aged 6 to 16 years with STRA were recruited from the Royal
Brompton Hospital (London, United Kingdom). They had already undergone
a detailed assessment to optimize adherence and address underlying modifi-
able factors as much as possible.17 STRA was defined as previously
described,1 as persistent chronic symptoms, exacerbations, or both despite
high-dose inhaled corticosteroids (beclomethasone equivalent >_800 mg/d),
long-acting b-agonists, and either current or a previous failed trial of leuko-
triene receptor antagonists. Two groups were defined: (1) patients with
SAFS with sIgE or positive SPT responses to any of A fumigatus, A alternata,
orC herbarum and (2) non–fungus-sensitized patients (non-SAFS) with nega-
tive sIgE levels and SPT responses to all these fungal allergens. Sensitivity to
other fungi is not routinely tested in our department. The study was approved
by the local research ethics committee, and informed parental consent and
child assent were obtained.Clinical assessment
Age at onset of symptoms, medications, and symptom scores (Asthma
Control Test)18 were recorded. Spirometry with bronchodilator reversibility
was performed according to American Thoracic Society/European
Respiratory Society guidelines.19Atopy
Atopy was assessed based on total serum IgE levels, sIgE levels, and SPT
responses to A fumigatus, A alternata, C herbarum, HDM, cat, dog, grass
pollen, peanut, milk, and egg. Atopy was defined as at least 1 positive sIgE
RAST result (>_0.35 kUI/L) or SPT response (wheal diameter, >_3 mm) to
aeroallergens (HDM, cat, dog, and grass pollen) and quantified as the sum of
these aeroallergens (sIgE levels and SPT-induced wheal diameters) and the
sum of all (nonfungal) allergens (aeroallergens and peanut, milk, and egg).20Airway inflammation and remodeling
Fraction of exhaled nitric oxide at 50 mL/s, (values <24 ppb were
considered normal) and results of induced sputum cytology1 were used to
assess eosinophilic airway inflammation noninvasively. Bronchoalveolar
lavage (BAL) and endobronchial biopsy inflammation and IL-33
expression and remodeling (reticular basement membrane thickness
and airway smooth muscle mass) were also quantified, as previously
described.1,21
Assessment of BAL mediators from pediatric
samples
The TH2 cytokines IL-4, IL-5, and IL-13 and other proinflammatory
cytokines (IL-6 and IL-8) were measured in BAL fluid by using a multiplex
cytokine assay (Luminex, Bio-Rad, Hemel Hempstead, United Kingdom).
IL-33 was not available as part of the assay, and reliable data could not be
obtained by using commercially available ELISAs. Therefore the molecular
size and quantity of IL-33 was determined by means of Western blotting.
BAL fluid protein levels were determined by using the BCA assay (Pierce,
Cheshire, United Kingdom). Five hundred nanograms of total protein of
each sample was loaded and run on a reducing gel before transfer to a
polyvinylidene fluoride membrane and blocking in 5% nonfat milk TBS-
Tween. Primary antibody (IL-33; R&DSystems, Abingdon, United Kingdom)
was incubated overnight at 48C at 1:1000 dilution. Secondary antibodies (New
England Biolabs, Hitchin, United Kingdom) were used at 1:2000 dilution and
incubated for 1 hour at room temperature. Bands were developed by with
ECL-Plus (Pierce) and imaged on film (Kodak, Rochester, NY). Densitometric
analysis was performed with ImageJ software (http://imagej.nih.gov/ij/). Ma-
trix metalloproteinase 9 (MMP-9) activity was determined by using Novex
10% zymogram gelatin gels (Invitrogen, Carlsbad, Calif).Neonatal allergic airways disease
Neonatal BALB/c or ST22/2mice underwent intermittent intranasal HDM
(20 mg for the first 2 weeks, followed by 25 mg) or saline exposure from day 3
of life for 3 weeks, as previously described.22 A alternata was administered
intranasally 3 times per week (5 mg for the first 2 weeks, followed by 10 mg
in the third week). Airway hyperresponsiveness (AHR) to methacholine was
determined by using the forced oscillation technique in anaesthetized and
tracheostomizedmice 4 hours after final challengewith HDMor 18 hours after
the final A alternata challenge, as previously described.22 In experiments to
assess the effects of steroid therapy, mice were treated with 0.6 mg/kg
intranasal budesonide (Pulmicort Respules; AstraZeneca, London, United
Kingdom) or PBS (10 mL) daily during the period of allergen exposure.
All experiments were performed in accordance with UK Home Office
guidelines.Tissue processing and analysis
Serum, BAL fluid, and lung tissue were collected and analyzed, as
previously described.22 Paired antibodies for murine IgE, (BD Biosciences,
Oxford, United Kingdom), IL-13, IL-33 (R&D Systems), IL-4, and IL-5
(PharMingen, Oxford, United Kingdom), were used in standardized sandwich
ELISAs, according to the manufacturer’s protocol. Serum HDM- and
A alternata–specific IgE was analyzed, as previously described.22Flow cytometry
Disaggregated lung cells were restimulated with 500 ng/mL ionomycin and
50 ng/mL phorbol 12-myristate 13-acetate in the presence of brefeldin (BD
PharMingen, Oxford, United Kingdom). Cells were stained for CD3, CD4,
IL-13 (eBioscience, San Diego, Calif), or lineage-negative cocktail (anti-CD3
[17A2], anti-CD45R [B220], [RA3-6B2], anti-CD11b [M1/70], anti–TER-
119 [TER-119)], anti–Ly-G6 [Gr-1, RB6-8C5; eBioscience], CD45 [eBio-
science], and inducible costimulator [ICOS; BioLegend, London, United
Kingdom]). Labeled cells were acquired on a BD Fortessa (BD Biosciences)
and analyzed by using FlowJo software (TreeStar, Ashland, Ore).
TABLE I. Patients’ demographics
Characteristics STRA with SAFS (n 5 38) Non–fungus-sensitized STRA (n 5 44) P value
Sex (male/female) 30/8 (male 5 78.9%) 22/22 (male 5 50%) .007
Age at symptom onset (y), median (range) 0.42 (0-12.5), n 5 36) 1 (0-12.5), n 5 43 .015
Atopy, no./total no. with data available (%) 37/38 (97.4) 33/44 (75) .004
Total IgE (IU/mL), median (range) 634 (24-6737), n 5 37 298 (7-4610), n 5 43 .015
Sum of nonfungal inhalant SPT wheal diameter (mm), median (range) 16 (3-38), n 5 27 9 (0-29), n 5 41 .008
Sum of nonfungal inhalant sIgE (IU/mL), median (range) 68.4 (0-287), n 5 33 30.8 (0-220.5) .02
Body mass index (kg/m2), median (range) 19.7 (7.1-29.7), n 5 18 18.3 (14.9-36.6), n 5 28 NS
Successful trial of omalizumab, no./total no. with data available (%) 8/10 (80) 11/18 (61) NS
Prescribed maintenance OCS, no./total no. with data available (%) 16/38 (42.1) 6/42 (14.3) .02
ICS dose (budesonide equivalent mg/d), median (range) 1500 (800-3000), n 5 38 1600 (800-4800), n 5 44 NS
ACT score, median (range) 13 (6-23), n 5 34 13 (6-25), n 5 40 NS
FEV1 (% predicted, median (range) 71 (29-121), n 5 38 71.5 (34-99), n 5 42 NS
FVC (% predicted), median (range) 94.5 (36-133), n 5 38 91.3 (57-123), n 5 42 NS
ACT, Asthma Control Test; FVC, forced vital capacity; ICS, inhaled corticosteroids; NS, not significant; OCS, oral corticosteroids.
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There are no data to inform a power calculation for the pediatric data, and
therefore the sample sizewas opportunistic. Statistical analysis was performed
with GraphPad Prism software (version 5; GraphPad Software, La Jolla,
Calif), and all data were analyzed by using nonparametric tests. Between-
group differences were analyzed with the Mann-Whitney test. If more than 2
groups were present, the Kruskal-Wallis test, followed by a Dunn correction
was used; x2 or Fisher exact tests were used, where appropriate (categorical
data); and correlations were assessed by using the Spearman correlation.
Values are expressed as medians with ranges.RESULTS
Clinical features of SAFS in children
Eighty-two patients (median age, 11.7 years; range, 4-17 years)
were included. Thirty-eight (46%) of 82 had SAFS. Demographic
data and clinical differences between the 2 groups are summa-
rized in Table I. Children with SAFS were predominantly boys
and had significantly earlier age of symptom onset. Patients
with SAFS had significantly higher total serum IgE levels and
sum of inhalant nonfungal allergen SPT responses and sIgE
results (Table I). Current symptoms and lung function, including
bronchodilator reversibility, were similar in children with and
without fungal sensitization. Airway inflammation and
remodeling were similar in children, regardless of fungal
sensitization (see Table E1 in this article’s Online Repository at
www.jacionline.org). Although lung function and pathologic
parameters were comparable in both groups, significantly more
children with SAFS were prescribed maintenance oral steroids
to achieve similar clinical status (P 5 .02, Table I).
Because SAFS was associated with higher serum IgE levels,
the clinical response to anti-IgE antibody therapy was assessed.
Twenty-eight of the 82 children included underwent a clinically
indicated trial of omalizumab, and 10 of 28 had SAFS. Eight
(80%) of 10 children with SAFS and 11 (64%) of 18 without
SAFS had a clinically beneficial response to omalizumab (not
significant, Table I).Children with SAFS had significantly more
pulmonary IL-33 and MMP-9 activity compared
to non-SAFS
We have previously shown A alternata–induced exacerba-
tions of allergic airways disease are mediated by IL-3316 andthat IL-33 is relatively steroid resistant.21 Because more chil-
dren with SAFS were receiving maintenance oral steroids, we
quantified IL-33 levels in BAL fluid and endobronchial biopsy
specimens comparing children with and without fungal sensiti-
zation. Children with SAFS had significantly greater BAL fluid
and tissue IL-33 levels compared with those who did not have
evidence of fungal sensitization (Fig 1, A and C, and see Fig
E1 in this article’s Online Repository at www.jacionline.org).
This remained true when children receiving maintenance oral
steroids were excluded (see Fig E2 in this article’s Online Re-
pository at www.jacionline.org), suggesting IL-33 is induced
by fungal sensitization. A recent adult murine fungal exacerba-
tion model demonstrated a relationship between IL-33 levels
and the protease and proremodeling mediator MMP-9.16 In
concurrence, BAL fluid MMP-9 activity assessed by using
gelatin zymography was significantly higher in children with
SAFS (Fig 1, C).Comparison of chronic A alternata exposure to
HDM exposure in neonatal mice
Becausemost children with STRA are polysensitized to several
aeroallergens, it is difficult to disentangle mechanisms
attributable to fungal sensitization alone. A alternata exposure
was compared with HDM exposure in neonatal mice (Fig 2, A)
to determine specific features of allergic airways disease resulting
from fungal sensitization. Both allergens induced similar
AHR (Fig 2, B). However, total serum IgE levels (Fig 2, C),
allergen-specific IgE levels (Fig 2, D), and total pulmonary
(Fig 2, E) and eosinophilic (Fig 2, F) inflammation were
significantly higher after A alternata exposure compared with
that seen after HDM exposure.Chronic A alternata exposure resulted in increased
IL-33 levels compared to HDM exposure
Because chronic A alternata exposure was associated with
enhanced IgE levels and inflammation, we determined TH2
cytokine levels after fungal exposure. Pulmonary IL-4, IL-5,
and IL-13 levels were similar after A alternata and HDM
exposure (Fig 3, A-C). However, BAL fluid IL-13 levels
were significantly higher after A alternata exposure (see Fig
E3, A, in this article’s Online Repository at www.jacionline.org).
FIG 1. Increased IL-33 levels (A) and MMP-9 activity (B) in BAL fluid and
increased submucosal IL-331 cell numbers in endobronchial biopsy
specimens (C) from children with STRA and SAFS compared with those
without fungal sensitization (no SAFS). There were 18 specimens for BAL
data, and 33 specimens for biopsy data. *P < .05 and ***P < .001.
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exposed to A alternata compared with levels in those exposed
to HDM (Fig 3, D), and BAL fluid MMP-9 levels were also
significantly higher after A alternata exposure than after
HDM exposure (Fig 3, E).
Because IL-33 is known to induce type 2 ILCs in the context
of adult models of allergic airways disease23 and levels of IL-
33 were significantly higher after A alternata compared with
HDM, we investigated whether type 2 ILCs might represent
the cellular source of IL-13 after A alternata exposure. Inter-
estingly, both pulmonary Lin2CD451ICOS1 ILCs and
CD31CD41 T cells were significantly increased after A alter-
nata exposure, and numbers were significantly higher when
compared with those after HDM exposure (see Fig E3, B
and C). Specifically, numbers of IL-131 ILCs and IL-131
TH2 cells were significantly higher in mice exposed to A alter-
nata compared with those seen in mice exposed to HDM (Fig
3, F and G). These data suggest fungal exposure results in
enhanced adaptive and innate type 2 immune responses in
neonatal mice.Neonatal ST22/2 mice exposed to A alternata had
significantly lower AHR and serum IgE levels
Neonatal ST22/2 mice, which lack a functional receptor for
IL-33, were exposed to A alternata for 3 weeks to confirm
whether IL-33 was a key pathogenic mediator in the development
of SAFS. ST22/2 mice had significantly reduced AHR in
response to A alternata (Fig 4, A and B), lower serum IgE levels
(Fig 4, C), lower pulmonary IL-13 levels (Fig 4, D), and fewer
IL-131 ILCs (Fig 4, E) compared with those found in wild-type
mice. Interestingly, there were no changes in lung IL-131 T-cell
numbers (Fig 4, F) and IL-4, IL-5, or IL-33 levels (see Fig E4,
A-C, in this article’s Online Repository at www.jacionline.org)
in ST22/2 mice, but MMP-9 levels were significantly reduced
(see Fig E4, D). These data suggest that AHR induced by chronic
fungal exposure is mediated by IL-33 through induction of
IL-131 ILCs.AHR is unaffected by steroid therapy after A
alternata exposure but is completely abrogated
after steroids and HDM exposure
We have shown that IL-33 is more steroid resistant than
IL-13.21 Because A alternata exposure resulted in higher IL-33
levels in the murine model and significantly more children with
SAFS were prescribed oral steroids to achieve similar symptom
control and lung function (Table I), we investigated whether
A alternata exposure induces a steroid-resistant phenotype of
allergic airways disease. Concomitant intranasal administration
of budesonide and allergen to neonatal mice (Fig 5, A) had no
effect on AHR after A alternata exposure (Fig 5, B), but
AHR was completely abrogated after HDM exposure (Fig 5,
C). A alternata– and HDM-induced total lung inflammation
were reduced to control levels after steroid treatment
(Fig 5, D), whereas eosinophilic inflammation was partially
reduced (see Fig E5 in this article’s Online Repository at
FIG 2. Fungal exposure in neonatal mice resulted in more severe atopy and inflammation than HDM
exposure, but AHR was similar with both allergens. Neonatal BALB/c mice were challenged with intranasal
HDM (20 mg for the first 2 weeks and then 25 mg) or A alternata (Alt; 5 mg for the first 2 weeks and then 10 mg)
for 3 weeks (A), and assessments of AHR (B), total serum IgE levels (C), allergen-specific IgE levels
(D), total pulmonary inflammation (E), and eosinophilic inflammation (F) were made. Data are
representative of 2 experiments (n 5 4-8 per group). *P < .05 and **P < .01. ns, Not significant.
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reduced after steroids and A alternata exposure but completely
abrogated after HDM exposure and steroids (Fig 5, E). Despite
steroid therapy, total serum IgE and IgG1 levels remained
significantly increased after A alternata exposure, whereas
both were reduced to control levels after HDM exposure (Fig
5, F and G).ILC2s, TH2 cells, and IL-13 levels remain elevated
after A alternata exposure despite steroid therapy
To determine why A alternata exposure resulted in steroid-
resistant AHR, we quantified ILC2 and TH2 cell numbers in
the lung after budesonide therapy. ILC2 numbers were not
increased after HDM, but TH2 cell numbers were reduced to
control levels after HDM exposure and steroids (Fig 6, A
and B). Both ILC2 and TH2 cell numbers were increased after
A alternata exposure and persisted despite steroids (Fig 6, A
and B). Lung IL-13 levels also remained increased despitesteroid therapy during A alternata exposure (Fig 6, C), corre-
lating with persistent AHR (Fig 5, B). Importantly, lung IL-33
levels remained increased after steroid treatment after both A
alternata and HDM exposure (Fig 6, D). Despite similarly
increased IL-33 levels after steroid treatment after both A
alternata and HDM exposure, a greater number of ILC2s
and TH2 cells only persisted after A alternata exposure (Fig
6, A and B), suggesting A alternata induces stronger type 2 im-
munity than HDM, thus resulting in a more severe phenotype
of allergic airways disease.DISCUSSION
We have reported the clinical and bronchoscopic features of
pediatric SAFS in a large cohort of patients and demonstrated a
potential novel mechanism that might drive fungal sensitization
in patients with this subphenotype of severe asthma. Children
with SAFS had earlier asthma onset and more severe atopy and
were prescribed more oral steroids than those not sensitized to
FIG 3. A alternata exposure resulted in significantly increased lung IL-33 levels, but lung IL-13 levels were
similar to those after HDM exposure. Pulmonary IL-4 (A), IL-5 (B), IL-13 (C), and IL-33 (D) levels; BAL fluid
MMP-9 levels (E); IL-131 Lin2CD451ICOS1 ILC numbers (F); and IL-131CD31CD41 T-cell numbers (G) in
neonatal BALB/c mice exposed to intranasal saline (PBS), HDM, or A alternata (Alt) for 3 weeks are shown.
Data are representative of 2 experiments (n 5 4-8 per group). *P < .05, **P < .01, and ***P < .001.
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activity than those without fungal sensitization. However,
there was no difference in symptoms, lung function, airway
inflammation (either in tissue or BAL fluid), or airway
remodeling, despite the higher levels of treatment in patients
with SAFS. Using age-appropriate experimental models of
chronic allergen exposure, we demonstrated increased IgE and
IL-33 levels and ILC2 and TH2 cell numbers in response to
A alternata exposure compared with those seen after HDM
exposure. AHR and IL-131 ILC2 and TH2 cell numbers remained
increased despite use of steroids after fungal exposure, but these
were significantly reduced in A alternata–exposed ST22/2 mice,
suggesting IL-33 is an important driver of SAFS. Therapeutic
strategies to block IL-33 might have better clinical efficacy in
patients with SAFS than the disappointing results of antifungal
agents.
The principle strength of this study is the inclusion of a large
number of children who have been carefully assessed after their
basic asthma management was optimized.17 In contrast to
adults,24 our children with SAFS were predominantly male.A recent report comprising children with asthma of a range of
severities also showed those with fungal sensitization were
more likely to have severe disease and higher IgE levels.4 IgE
levels might not be strictly comparable between adults and
children because the adult SAFS definition had an upper cutoff
of 1000 IU/mL to ensure patients with ABPAwere not included.11
ABPA is very rare in asthmatic children, and indeed, none of this
group met the criteria for diagnosis; therefore we have not
adopted this cutoff. None of our children were given a diagnosis
of or treated for ABPA. We also extended these observations by
quantifying atopy as the sum of sIgE or SPT results,20 again
showing that children with SAFS were more atopic (to nonfungal
inhalant allergens). We have only studied 3 of 7 fungi implicated
in the adult definition of SAFS becausewe do not routinely test for
sensitivity to other fungi. However, this could only have resulted
in some children with SAFS being incorrectly placed in the
control group, biasing against us finding any significant
differences.
Although we did not see differences in inflammation in our
children with and without SAFS, this is likely because the
FIG 4. Neonatal ST22/2mice have significantly reduced allergic airways disease after A alternata exposure
compared with wild-type mice. Neonatal mice were exposed to intermittent intranasal A alternata (Alt; 5 mg
for the first 2 weeks and then 10 mg) or saline (PBS) from day 3 of life for 3 weeks. AHR (A and B), total serum
IgE levels (C), pulmonary IL-13 levels (D), and IL-131Lin2CD451ICOS1 ILCs (E) and IL-131CD31CD41 T cells
(F) were assessed. Data are representative of 2 experiments (n 5 6-8 per group). *P < .05 and **P < .01.
MCh, Methacholine; ns, not significant.
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medications. Even though more children with SAFS were
prescribed oral steroids, more than half still had BAL fluid
and sputum eosinophilia (see Table E1), suggesting fungal
sensitization might be associated with steroid resistance. We
have previously shown that the innate cytokine IL-33 is relatively
steroid resistant and that tissue expression is increased in children
with severe asthma (regardless of fungal sensitization).21 In
addition, IL-33 levels are significantly increased after a single
dose of A alternata in an adult murine model.16 Therefore we
determined BAL fluid and endobronchial biopsy specimen
IL-33 levels in the children with severe asthma and showed that
they were higher in patients with SAFS. This suggested that
IL-33 might be important in mediating fungal sensitization in
pediatric patients with severe asthma.Because the children’s data were cross-sectional and only
very small airway samples could be obtained, studies to confirm
the functional role of IL-33 in mediating SAFS could not be
performed in the patients. Therefore we used an age-appropriate
experimental model to assess mechanisms that might underlie
fungal sensitization. Importantly, the children were polysensi-
tized to numerous aeroallergens, but to determine specific
mechanisms attributable only to fungal exposure, we compared
a neonatal mousemodel of chronic HDMexposurewith chronicA
alternata exposure. The dose of each allergen was equivalent
because similar AHR was generated after the same duration of
exposure. Even though the dose of HDM (20mg) used was double
our previously published dose22 and 4 times greater than the
A alternata (5 mg) dose, significantly more inflammation
and greater IgE and IL-33 levels were induced by A alternata.
FIG 5. AHR is unaffected by steroids after A alternata exposure, whereas inflammation and serum IgE levels
are reduced. A, Neonatal BALB/c mice were exposed to intranasal (I-N) saline (PBS), HDM, or A alternata
(Alt) from day 3 of life for 3 weeks, with concomitant intranasal budesonide (0.6 mg/kg) or PBS from day
10 of life for 2 weeks (prevention regimen). B-G, AHR (Fig 5, B and C), total lung inflammation (Fig 5, D),
BAL inflammation (Fig 5, E), and serum immunoglobulin levels (Fig 5, F and G) were assessed (n 5 4-6
per group [PBS] or n 5 6-8 per group [HDM or Alt]. *P < .05 and **P < .01. MCh, Methacholine; ns, not
significant.
J ALLERGY CLIN IMMUNOL
VOLUME 136, NUMBER 2
CASTANHINHA ET AL 319The neonatal model of fungal exposure mirrored the pediatric
data, with increased IgE levels after A alternata compared with
those after HDM exposure. There was also increased eosinophilia
after A alternata exposure in the murine model. Although the
effects of chronic A alternata challenge are associated
with increased IL-33 levels25 in experimental models, direct
comparisons of IL-33 release after fungal and nonfungal allergen
exposure have not been made. Adult models of A alternata
exposure have shown increased ILC numbers without increasedT- or B-cell numbers.26,27 However, in our neonatal model
A alternata increased pulmonary IL-33 levels concomitant with
an increase in both TH2 cell and ILC2 numbers compared with
HDM exposure. This suggests that both cell types might be
induced by IL-33 in early life. A limitation was our inability to
demonstrate an association between IL-33 levels and increased
ILC2 or TH2 cell numbers in children with SAFS. However, the
limited volume of BAL fluid obtained prevented detailed cellular
characterization, and only mediators could be quantified.
FIG 6. Steroids did not reduce IL-33 levels. Lung IL-13 levels and IL-131 ILC and IL-131 T-cell numbers only
remained increased after steroids with A alternata exposure. Neonatal BALB/c mice were exposed to
intranasal saline (PBS), HDM, or A alternata (Alt) for 3 weeks from day 3 of life, with either concomitant
intranasal budesonide or saline (PBS). Lung IL-131Lin2CD451ICOS1 ILCs (A) and IL-131CD31CD41 T cells
(B)were quantified by means of flow cytometry. Levels of pulmonary IL-13 (C) and IL-33 (D)were measured
by means of ELISA. There were 4 to 6 per group for the PBS group and 6 to 8 per group for the HDM or
A alternata groups. *P < .05, **P < .01, and ***P < .001. ns, Not significant.
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exposure results in relatively steroid-resistant AHR in neonatal
mice. Treatment with daily inhaled steroids in a prevention
regimen at a dose equivalent to that used in children with
STRA (before allergic airways disease was established) did not
alter AHR in the A alternata model. In contrast, AHR was
completely abrogated with the use of steroids in a similar regimen
with HDM exposure. We have previously shown that steroids in a
therapeutic regimen only partially reduce AHR in our neonatal
HDM model,21 but with the current prevention regimen, HDM-
induced AHR is steroid sensitive, whereas A alternata–induced
AHR is steroid resistant. Despite steroids, pulmonary IL-33 levels
and IL-131 TH2 cell and ILC2 numbers remained increased after
A alternata exposure. Although IL-33 levels remained similarly
increased after steroids during exposure to both allergens,
significantly more ILC2s were induced by A alternata than
HDM, and although there was a partial reduction in ILC2
numbers after steroids, they remained significantly higher than
in HDM-exposed mice after steroids, thus resulting in higher
lung IL-13 levels and AHR. Interestingly, BAL fluid IL-13 was
completely abrogated by steroids after A alternata exposure
(data not shown), but we know that lung IL-13 levels most
closely reflect AHR in our neonatal model.22 This finding in
BAL fluid concurs with our previous clinical findings of very
low/undetectable BAL fluid IL-13 levels in children with
STRA.1 We have also assessed levels of IL-13 and other
TH2 cytokines in BAL fluid from the children according tofungal sensitization status, but levels did not correlate
with SAFS (see Fig E6 in this article’s Online Repository at
www.jacionline.org).
Although previous experimental studies reported an associa-
tion between IL-33 levels and fungal exposure,16,25,26,28,29 to our
knowledge, this is the first to show directly, using ST22/2 mice,
that chronic fungal sensitization is mediated by IL-33. In
addition, a relationship between steroid resistance and fungal
sensitization has not been reported. We have also confirmed
such an association in patients with STRA, thus identifying a
novel mechanism underlying SAFS and a potential novel
therapeutic target. IL-33 is likely a specific therapeutic target
for pediatric SAFS because we have been unable to detect
increased levels of the other innate cytokines IL-25 or thymic
stromal lymphopoietin in either our neonatal mouse model of
allergen exposure or in BAL fluid from children with STRA.21
This is important because the only SAFS-specific therapeutic
approach adopted to date has been the use of antifungal agents.
However, there is a risk of adverse interactions between itracona-
zole and inhaled corticosteroids that might lead to iatrogenic
Cushing syndrome.30 Moreover, antifungal therapy in patients
with SAFS shows variable efficacy whereby itraconazole resulted
in improved quality of life14 but was also associated with a 40%
failure rate.13 Although voriconazole and posaconazole as
second- and third-line antifungal agents might be promising
therapies,13 a randomized placebo-controlled trial of voriconazole
in adults with asthma sensitized to A fumigatus with at least 2
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benefit on exacerbations or quality of life.15 There are no
interventional studies of antifungal agents in children with
SAFS. However, given the varying effect from adult studies to
date and that only one of the 82 children included in this study
had positive fungal growth from BAL fluid, antifungal therapy
might not be beneficial. We did not introduce antifungal agents
into our neonatal mouse model because oral itraconazole during
HDM exposure of adult mice plus short-term A fumigatus
inhalation reduced eosinophilic and neutrophilic inflammation
but had no effect on IL-5 or IL-13,31 and our previous data
show IL-13 is most closely related to AHR.22 Interestingly,
additional treatment with the steroid dexamethasone also did
not reduce IL-13 levels after HDM and A fumigatus exposure,
suggesting agreement with our data that any fungal exposure
causes reduced steroid sensitivity.
An important feature of SAFS apparent from both our human
and murine data was significantly increased serum IgE levels.
Therefore anti-IgE mAb therapy (omalizumab) could be
proposed as a preferred treatment option in patients with SAFS.
However, in our cohort there was no significant difference in
clinical response to omalizumab between patients with and
without fungal sensitization in the relatively small numbers
treated (Table I). This suggests the effects of blocking IgE are
not specific enough to affect the disease severity and AHR caused
by fungal sensitization.
We have previously shown that children with STRA have
increased airway remodeling compared with that seen in
nonasthmatic control subjects.1 However, when we looked at
reticular basement membrane thickness and smooth muscle
mass, there were no differences between children with and
without SAFS. This might be because all children had severe
disease and established remodeling very early, which is similar
to the situation in adult patients.32 However, in a recent adult
fungal exacerbation murine model, a relationship between
IL-33 levels and levels of the protease and proremodeling
mediator MMP-9 was demonstrated.16 Therefore MMP-9
activity was measured in pediatric BAL fluid and showed
significantly increased levels in children with SAFS. This was
confirmed in BAL fluid from A alternata–exposed neonatal
mice. MMP-9 is a downstream target of IL-33,16 and activity
is increased in sputum from patients with severe asthma who
are unresponsive to steroid therapy.33 Both IL-33 and MMP-9
activity was increased in the BAL fluid of our patients. Because
we have previously shown an association among IL-33 levels,
airway remodeling, and steroid resistance, higher IL-33 levels
in patients with SAFS might contribute to airway remodeling
through MMP-9. MMP-9 is a sensitive indicator and
mediator of airway remodeling activity34 rather than established
remodeling and can be more easily measured in sputum and
BAL samples33,35 than IL-33, suggesting it could be used as a
soluble biomarker to assess therapeutic response to blocking
IL-33 in patients with SAFS.
It is acknowledged that the mechanisms underlying SAFS are
complex and the role of immunomodulating agents requires
investigation.36 However, we report a novel association between
steroid-resistant IL-33–induced AHR mediated by ILC2 and
TH2 cells and the development of SAFS and propose IL-33 as a
potential therapeutic target for this subphenotype of severe
asthma.Key messages
d Pediatric SAFS is associated with increased IL-33 levels
and increased oral steroid therapy.
d Neonatal allergic airways disease induced by chronic
A alternata exposure is steroid resistant, with higher
IL-33–mediated ILC2 and TH2 cell numbers compared
with those after HDM exposure.
d The steroid-resistant cytokine IL-33 might be a novel
therapeutic target for SAFS.REFERENCES
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FIG E1. IL-33 levels were quantified in BAL fluid by means of Western blotting (A), and IL-331 cells stained
by means of immunohistochemistry were quantified in the submucosa of endobronchial biopsy specimens
(B; n 5 14 children). Group differences were assessed by using the Mann-Whitney U test: *P < .05. ns,
Not significant.
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FIG E2. Endobronchial biopsy specimens from children aged 6 to 16 years
with severe asthma receiving high-dose inhaled steroids only were stained
by using immunohistochemistry for IL-33 expression. IL-331 cells in the
submucosa were counted and expressed per area of submucosa in children
with SAFS compared with children with severe asthma without fungal
sensitization (no-SAFS; n 5 2). Group differences were assessed by using
the Mann-Whitney U test: **P < .01.
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FIG E3. Neonatal BALB/c mice were exposed to intermittent intranasal A alternata (Alt), HDM, or saline
(PBS) for 3 weeks. Total BAL fluid IL-13 levels were measured by means of ELISA (A), and numbers
of Lin2CD451ICOS1 ILCs (B) and CD31CD41 T cells (C) were quantified by means of flow cytometry.
*P < .05, **P < .01, and ***P < .001. ns, Not significant.
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FIG E4. Neonatal ST22/2 and wild-type mice were exposed to intermittent intranasal A alternata (Alt; 5 mg
for the first 2 weeks and then 10 mg) or saline (PBS) from day 3 of life for 3 weeks. Levels of IL-4 (A), IL-5
(B), IL-33 (C), and MMP-9 (D) were measured in lung homogenates (LH) by means of ELISA. Data are
representative of 2 experiments (n 5 6-8 per group). *P < .05.
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FIG E5. Neonatal BALB/c mice were exposed to intranasal saline (PBS), HDM, or A alternata (Alt) from day 3
of life for 3 weeks, with concomitant intranasal budesonide (0.6mg/kg) or PBS from day 10 of life for 2 weeks
(prevention regimen). These data relate to the same experiment shown in Fig 5. Numbers of eosinophils
were quantified by means of flow cytometry in lung digests after A alternata exposure (A) and HDM
exposure (B) with and without budesonide (Bud; n 5 4-6 per group for PBS and n 5 6-8 per group for
HDM or A alternata. *P < .05 and **P < .01.
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FIG E6. Endobronchial biopsy specimens from children aged 6 to 16 years with severe asthma were stained
by means of immunohistochemistry for IL-13 expression. A, IL-131 cells in the submucosa were counted
and expressed per area of submucosa in children with SAFS compared with children with severe asthma
without fungal sensitization (no SAFS). B-E, IL-13 (Fig E6, B), IL-5 (Fig E6, C), IL-6 (Fig E6, D), and IL-8
(Fig E6, E) levels in BAL fluid from children with SAFS and non-SAFS were quantified by using the Luminex
multiplex assay (Bio-Rad). ns, Not significant.
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TABLE E1. Inflammation and remodeling in children with STRA with and without fungal sensitization
Parameter
STRA with fungal
sensitization (n 5 38)
Non–fungus-sensitized
STRA (n 5 44)
P
value
FENO (ppb), median (range) 30.5 (4.8-170), n 5 38 55.7 (3.4-231), n 5 40 .012
Sputum eosinophils (%), median (range) 4 (0-67), n 5 20 6.9 (0-92), n 5 22 .3
Sputum neutrophils (%), median (range) 36 (5-86), n 5 20 24 (0-97), n 5 22 .5
BAL eosinophils (%), median (range) 2.7 (0-16), n 5 31 2.3 (0-51), n 5 33 NS
BAL eosinophilia (>1.19%), no./total no. with data available (%) 22/36 (55) 29/40 (72.5) NS
BAL neutrophils (%), median (range) 4 (0-75), n 5 31 3.3 (0-74), n 5 33 NS
BAL neutrophilia (>3.5%), no./total no. with data available (%) 19/36 (52.8) 18/38 (47.4) NS
RBM thickness (mm), median (range) 7.12 (4.8-13.1), n 5 24 7.7 (4.3-11.4), n 5 33 NS
ASM mass Vv (sm/subepithelium), median (range) 0.22 (0.05-0.65), n 5 19 0.16 (0-0.55), n 5 28 NS
ASM mass Vs (sm/subepithelium), median (range) 26.3 (6.8-83.5), n 5 14 18.9 (0.7-81.6), n 5 20 NS
Epithelial shedding (% epithelial loss), median (range) 90.3 (68.9-100), n 5 23 92.5 (17.7-100), n 5 29 NS
ASM, Airway smooth muscle; FENO, fraction of exhaled nitric oxide; NS, not significant; RBM, reticular basement membrane; Vs, subepithelial volume fraction of airway smooth
muscle indexed to surface area of RBM; Vv, subepithelial volume fraction of airway smooth muscle indexed to subepithelial tissue.
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